ALZINOVA Image
IMAGE INFORMA.COM.AU

ALZINOVA

MARKET CAP - 75M SEK
MARKET CAP - 75M SEK

ABOUT US

Alzinova was co-founded by Dr Anders Sandberg and Prof Torleif Härd with the mission to develop an effective therapeutic and bring relief to AD patients. Alzinova’s development and market strategy is based on the proprietary AβCC peptide technology. Today, Alzinova is an established knowledge-based company with a vision to develop an AD treatment suitable for most international markets. The potential of ALZ-101 has been recognised by external experts and innovation funding bodies. The goal is to take the product through the clinical Phase 1b safety and immunogenicity study and thereafter out-license to a strong partner.

Q&A WITH KRISTINA TORFGåRD  

Right arrow

What have been the milestones so far in your company development?

Awaiting.

Right arrow

What are your most important markets, segments and customers?

Awaiting.

Right arrow

Where do you see the company five years from now?

Awaiting.

Right arrow

What are your priorities within 2020/21?

Awaiting.

Right arrow

Why should one consider adding your company into their portfolio?

Awaiting.

PRODUCTS & SERVICES

ALZINOVA Image
ALZINOVA Image
ALZINOVA Image